Antitrust Antitrust

Comment: Teva’s EU troubles broaden amid claims of blocking generic access

By Lewis Crofts and Max Fillion
  • 12 Nov 2020 11:44
  • 13 Nov 2020 10:02
Teva is facing an EU dominance probe into a treatment for multiple sclerosis, against a backdrop of evidence in the US that the company has been using “exclusionary tactics” through pharmacies and prescriptions to keep cheaper versions off the market.
A recent report by US lawmakers accused Teva of illegal

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Lewis Crofts


Lewis leads MLex's editorial strategy, content direction, quality and development. He has a reputation for breaking stories and providing analysis on complex legal disputes before regulators and courts around the globe. He has also developed MLex's unrivalled coverage of competition policy, litigation, regulation, Brexit and international investigations.

Discover MLex

Stay on top of global regulatory developments

Latest News